Multi-country agreement to develop, commercialize drugs for dermatological conditions signed
- Mon, 6/25/12 - 9:20am
- 0 Comments
- 1019 reads
AmDerma Pharmaceuticals, LLC (Bridgewater, NJ) and Oculus Innovative Sciences (Petaluma, CA) announced the execution of an agreement to develop and commercialize Oculus' novel proprietary Microcyn® Technology drug compounds for major dermatological conditions, including acne. The exclusive agreement includes licensing of the dermatology compounds in the US and India, with a first right of refusal for all member states of the European Union, Canada, Brazil, and Japan. Oculus retains all rights for the rest of the world.
AmDerma will be responsible for the development costs for the acne formulation, as well as other dermatological compounds.
For more information, visit www.oculusis.com.